DGAP-Adhoc
Elanix Biotechnologies AG: capital increase successfully placed, gross issuing proceeds amount to some EUR 4.76 million - Seite 2
company was founded in 2013 as a spin-out from the University Hospital of
Lausanne (CHUV), Switzerland, to commercialize a patented progenitor cell
technology. Progenitor cells are fully differentiated yet immunologically
neutral cells that are very potent inducers of tissue growth and healing.
Elanix owns GMP certified Master and Working cell banks with vast
quantities of cells of different cell types.
The Company is headquartered in Nyon, Switzerland, with offices in Potsdam,
and is listed on the Frankfurt stock exchange under the symbol ELN. For
more information and updates, visit www.elanix-biotechnologies.com.
Disclaimer
This publication contains forward-looking statements subject to certain
risks and uncertainties. Actual results may be materially different from
those expressed or implied by such statements due to a variety of risk
factors and uncertainties such as changes in the business, economic and
competitive situation, exchange rate fluctuations, uncertainties regarding
litigation or investigation proceedings and the availability of financial
resources. Readers should therefore not place undue reliance on these
statements, particularly not in connection with any contract or investment
decision. The Elanix Biotechnologies AG disclaims any obligation to update
these forward-looking statements.
Lesen Sie auch
This communication does not constitute an offer or invitation to subscribe
for or purchase any securities of Elanix Biotechnologies AG. This
announcement does not contain or constitute an offer of, or the
solicitation of an offer to buy or subscribe for, securities to any person
in the United States of America (the "United States"), Australia, Canada or
Japan or in any jurisdiction to whom or in which such offer or solicitation
is unlawful. The securities referred to in this announcement will not be
and have not been registered under the U.S. Securities Act of 1933, as
amended (the "U.S. Securities Act") and may not be offered or sold in the
United States absent registration or an applicable exemption from
registration requirements under the U.S. Securities Act. Subject to certain
exceptions, the securities referred to in this announcement may not be